Nowadays molecular imaging plays a vital role in achieving a successful targeted and personalized treatment. Hence, the approach of combining two or more medical imaging modalities was developed. The objective of this review is to systematically compare recent dual contrast agents in Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) and in some cases Single photon emission computed tomography (SPECT)/MRI in terms of some their characteristics, such as tumor uptake, and reticuloendothelial system uptake (especially liver) and their relaxivity rates for early detection of primary cancer tumor. To the best of our knowledge, this is the first systematic and integrated overview of this field. Two reviewers individually directed the systematic review search using PubMed, MEDLINE and Google Scholar. Two other reviewers directed quality assessment, using the criteria checklist from the CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies) tool, and differences were resolved by consensus. After reviewing all 49 studies, we concluded that a size range of 20-200 nm can be used for molecular imaging, although it is better to try to achieve as small a size as it is possible. Also, small nanoparticles with a hydrophilic coating and positive charge are suitable as a T 2 contrast agent. According to our selected data, the most successful dual probes in terms of high targeting were with an average size of 40 nm, PEGylated using peptides as a biomarker and radiolabeled with copper 64 and gallium 68.
1. INTRODUCTION
Molecular imaging
Nowadays most clinicians trying to reach a successful targeted and personalized treatment believe that molecular imaging plays a vital role in achieving this aim. Thanks to molecular imaging the biological targets can be visualized and their complexities for diagnosis and treatment of the disease can be better understood (1) (2) (3) . As the Society of Nuclear Medicine has described, molecular imaging can lead to the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems, therefore imaging of biological targets results in early detection of various diseases effectively (4) . There are different imaging modalities such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), Ultrasound (US), and Optical Imaging (OI). Each of the mentioned modalities has its own pros and cons. In order to obtain all the required information about the biological processes and function of an organ, we need to combine two or more modalities to use their advantages and weaken their disadvantages. This approach results in a better reliability of the images (1). Table 1 lists the different types of devices used in molecular imaging and describes their advantages and disadvantages. Also, it briefly mentions some current probes utilized in the imaging device.
Multimodality imaging
Concerning the advantages and disadvantages of imaging modalities to obtain a combination of anatomical, functional and molecular information, multi-modality imaging was suggested. In this approach, images from different modalities taken at the same point are combined in order to use the strengths of the different modalities and yield a hybrid imaging platform with characteristics superior to those of any of its constituents considered alone. In fact, utilization of the high-resolution information coming from an anatomical or functional image in order to improve the imaging performance of the low-resolution modality is the most important feature.
At the beginning, images of different modalities were acquired separately and then merged. However, due to the possibility of different positioning of the patient in the two modalities and also of inaccurate co-registration due to movement, the simultaneous acquisition of images was suggested. The first multimodal devices (SPECT/CT and PET/CT) were introduced commercially in 1998 (5).
Using dual modality probes in the clinic, physicians may benefit from not only anatomical data but also physiological (or functional) data from a single image. In addition, since some contrast agents in MRI produce negative contrast, using dual modality images enables them to ensure the existence of the probe and quantification of the uptake quantity. Therefore, the combination of anatomical and functional data by multimodal techniques, enhancement of contrast in molecular imaging and, therefore, the increase of diagnostic capabilities are other benefits (6) .
Furthermore, the use and development of dual-modality contrast agents in some cases, such as manipulation of nano agents, will increase the tumor uptake and tumor retention.
PET/MRI
Combining positron emission tomography (PET) and magnetic resonance imaging (MRI) was presented as an idea even before PET/CT (7) . The first PET/MRI systems consisted of PET and MRI elements individually and connected by a table; there were some limitations, such as misregistration due to temporal separation of the data acquisition and the need for a large room to place the equipment (8) . In order to remove these problems, the fully integrated PET/MRI was designed. The main goal in the development of this dual-modality imaging system was benefiting from the high anatomical spatial resolution and good soft tissue contrast of MRI and the unparalleled sensitivity and noninvasive functional molecular imaging of PET (4, 9, 10 ). Another advantage of this hybridization was a shorter scan time (8).
Advantages
From a scientific and clinical point of view, an integrated PET/MRI may have some benefits over PET/CT imaging:
1. The greater contrast of soft tissue obtained with MRI (compared to CT), even without the use of contrast agents, allows Biographies Afsaneh Lahooti is a PhD student in Medical Physics at Tehran University of Medical sciences. She has received some awards such as the outstanding lecturer in the 11th Annual General Meeting of ARCCNM in Seoul, Korea, (2012), best poster award from IAEA in the 2 nd World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) in Chandigarh, India, (2013) and she won several grants from IAEA. At present, she is in the fourth year of her thesis. Her research interest is development and evaluation of the dual modality nano probe in PET/MRI for Molecular imaging of Breast cancer. She is currently focused on development of active targeting of breast cancer cells in in-vitro and in-vivo studies using SPION conjugated with a peptide. Her previous research was on external dosimetry in Radiotherapy and also internal dosimetry in Nuclear medicine based on MIRD protocol for estimating human dose from rat data. (11, 12) . However, to show small lung nodules, bone, and bone structures, CT is still more sensitive than MRI (13) . Also, MRI is capable of measuring other factors that can characterize malignancies and their patient-specific biological properties (12) . These factors regularly evaluated today include blood vessels generated by a tumor and perfusion properties through dynamic contrast enhancement [DCE] imaging (14) . DCE without the rather high radiation dose, as compared to CT-based perfusion measurements, can help evaluate intravascular treatments. Another MRI method called Diffusion Weighted Imaging (DWI) provides information related to tumor cells and the integrity of the cellular membrane. It has the ability to determine treatment response to chemotherapy and radiation treatment (12, 15, 16 (20) . But for N-staging, the performances of MRI and PET/CT are similar. It should be mentioned that the use of new lymphotropic superparamagnetic nanoparticles (NPs) can offer new opportunities for the detection of nodal micro metastases that is not possible with PET/CT (21) . For Mstaging, it has been claimed that MRI may provide higher accuracy for detection of lesions, particularly in the brain, liver, and bone (20) . Furthermore, PET/MRI offers interesting opportunities for use of dual modality probes in both research and clinical fields (20) . In recent years, the interest in hybrid imaging, especially PET/MRI, in cardiovascular studies is increasing. This is because of MR-based motion correction of PET images that allows improved evaluation of myocardial perfusion, providing viability information in plaque imaging and MR angiography (22) . Further interesting applications of PET/MRI are the early diagnosis of neurodegenerative disorders and dementia (23) , the detection of epileptic foci (24) , monitoring glucose metabolism and cerebral blood flow or oxygen consumption for the investigation of focal brain ischemia (12).
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4. In fully integrated systems, MRI could also be used to provide a gating signal in addition to imaging. However this is only advantageous when MR data acquisition, MR gating data, and PET data are acquired simultaneously and for similar amounts of time, as otherwise MR is just an expensive device to provide gating information for PET.
5. The main advantage of MRI is a lack of ionizing radiation especially for a patient with a non-oncological disease or a potentially curable oncological disease. But it is not important for oncological patients (17, 25, 26) . 6. Combined PET/MRI may decrease the imaging time; thus, by reducing appointment periods, department logistics have to be improved (17,26).
Disadvantages (challenges)
Although several investigations were performed to find solutions for some disadvantages of PET/MRI, there are still several challenges in combining PET and MRI. Therefore, more studies must be designed and implemented to solve them properly. We will mention some of these disadvantages and their solutions.
1. One of the main challenges in totally integrated PET/MRI system is developing a PET detector that is compatible with MRI. Whereas the conventional detectors cannot operate accurately in or even near a magnetic field, especially between of 0.5 to 10 tesla (indeed the paths of electrons are perturbed by the magnetic field) (27), some solutions have been proposed: a) Shielding electronics against the magnetic field for avoiding the effects of the changing gradient field and radiofrequency pulses of MRI. b) The new generation of detectors, avalanche photodiode detectors (APD), can be used as a detector in PET instead of photomultiplier tubes (PMT) (28) . Magnetic fields do not affect these new detectors (29, 30) ; therefore, they can be placed in an MRI magnet without any degradation in performance. In addition, the potential of another type of detector called silicon photomultiplier (SiPM) as a possible replacement in PET has been confirmed recently (31). 2. The gradient magnetic field in MRI is one of the other interferences in a PET system. Since the fast switching of magnetic fields can induce eddy current loops in conductive components, heating, and mechanical vibration, this must be solved for example by shielding electronics, as was mentioned in the previous item (27) . 3. In addition, radio frequency (RF) interference created by the MRI transmission coil may affect electronic components. RF shielding around PET is the effective way to decrease its effect. But unfortunately, the shielding can induce eddy currents and heating individually (27). 4. The additional challenge is placing the PET detectors inside the limited space of the MRI bore, which imposes other challenges to the detector technology (27). 5. Attenuation correction for PET images is vital, since one of the causes of image degradation in all nuclear medicine emission imaging techniques (especially PET) is variable photon attenuation in different tissues (12, 32) . It should be mentioned that MR images give information about tissue proton densities and magnetic relaxation times, not photon attenuations (12, 17) . Although the attenuation correction methods proposed by combined MRI/PET systems, based on segmentation methods of MR images for preparing the total attenuation map, are developed enough to use them clinically, the problem is not yet completely solved and remains an active area of research (27, 33, 34) . 6. Because PET imaging usually takes a long time, motion problems are inevitable (34) . This leads to blurring of tumors in PET images and may even entirely obscure the presence of smaller lesions (33) . Also, in the case of motion with large amplitude, it causes severe artifacts (34) . In general, motion can be one a source of errors in both lesion localization and quantification (35) . Three major types of motion are (33): a) Gross motion: head movement or subtle patient repositioning due to discomfort. b) Periodic movement: cardiac and respiratory motion. c) Internal shifting and distortion in the pelvic and abdominal regions.
To solve the problems related to motion:
a) The first way is using high spatial resolution MR images to correct for PET motion with affectedly reduction of the spatial blurring and artifacts associated with PET movement of solid organs (34) . But inappropriately, this imaging covers a large field of view (FOV) and takes a few minutes that can cause motion individually (33). b) Another solution is the use of external tracking devices and video cameras to record the movements as used in cardiac and respiratory gating (36,37).
OBJECTIVE
The objectives of this review is to evaluate the detection efficiency, specificity, and targeting capability of dual contrast agents in PET/MRI and SPECT/MRI for early detection of primary cancer tumor and specially breast cancer.
METHODS AND MATERIALS

Identifying studies search strategy
Two reviewers individually directed the systematic review search using PubMed, MEDLINE, and Google Scholar. The following keywords were used: ('Dual contrast agent' or 'Multimodal imaging' or 'hybrid imaging' or 'dual probe') AND ('magnetic resonance imaging' or 'positron emission tomography' or 'PET/MRI'). There was a restriction date between 2008 to the end of 2015 and confined to English language articles.
Selection of studies
Studies were included according to the following criteria: 1) published in English with full-text available; 2) using NPs as the base of the contrast agent; 3) using PET/MRI or SPECT/MRI imaging; 4) performing in vivo imaging or in vivo biodistribution or both; and 5) using radionuclides with or without chelator. Studies were excluded if they included PET/CT imaging. Differences of opinion between the two reviewers were resolved by compromise. In order to have a precise comparison of our data, we asked for additional data from the authors of eleven studies. Nine responded whereas two did not respond and had to be excluded.
Quality assessment
Two reviewers directed quality assessment, using a criteria checklist from the CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies) tool, and differences resolved by consensus.
RESULTS AND DISCUSSION
We extracted the important data from the 49 selected studies. All data are presented in Table 2 . The data is shown is the clearest way possible.
Liver uptake
In the 49 selected studies, we evaluated the liver uptake and the reasons for that. Some studies aiming at lymph node (LN) imaging, report LN uptake; although, liver uptakes were not considerable. Iron oxide and superparamagnetic iron oxide nanoparticles (SPION) are the base of the agents used. In order to achieve the desired diameter (in a narrow size range) of those SPIONs essential for LN imaging, they should be produced in a systematic way. For two compounds, 68 Ga-SPION and 99m Tc-SPIONs, the biodistribution data showed that a small amount of them were transported by the lymph through other nodes and finally accumulated in the liver and spleen (38, 39) . Table 3 presents the best three studies which had the highest amounts of lymph node uptakes. Since the benefits of using PET in comparison with SPECT imaging in the clinic are higher sensitivity, reduced dose, greater resolution, and critically reduced partial volume effects, the development of PET/MRI contrast agents like 89 Zr-ferumoxytol can allow mapping of the draining lymphatics and provide information-rich preoperative mapping as well as increase intraoperative confirmation (40) . Among all three studies in Table 3 , the liver uptake of 89 Zr-ferumoxytol was the highest, 6.11 %ID/g, maybe because of the dextran coating (40) , since the other compounds had PEG coating and had lower liver uptakes. On the other hand, the comparison between the Sentinel Lymph Node (SLN) uptakes showed that a bigger size of contrast agent causes a greater SLN/Liver uptake (38) . However, we cannot state that as a rule since there are contradictory results in other articles, like that of Natarjan et al. (41) . The section in this review dedicated to size will discuss in more detail the effect of size on liver uptakes.
From all studies which mention the amount of liver uptake at different time points, we conclude that the highest liver uptake belongs to 99m Tc-DPA-ale-Endorem (Dipicolylamine-alendronate (DPA-ale)), with an uptake of 96.9 AE 0.9 %ID. Since Endorem is a clinically approved and colloidally stable MRI contrast agent and is taken up by cells of the reticuloendothelial system (RES), such as monocytes, macrophages, and Kupffer cells, this result was expected. Moreover, the size of this compound (106 AE 60 nm) and its dextran coating are other reasons that cause high liver uptake. In the reported study, by measuring and evaluating the variations of T 2 * values from the short-axis images, the accumulation of 99m Tc-DPA-ale-Endorem in the liver was calculated as well (42) .
In three of the studies, we found approximately equal liver uptake 24 hours after administration (43) (44) (45) . The large accumulation in the liver is because of scavenging and phagocytosis by cellular elements of the RES. Furthermore, all of the NPs used had PEG coating. These reasons could be the cause of a nearly equal liver uptake.
Finally, the lowest liver uptake was found in one of the studies which used two compounds, 68 Ga-NODAGA-AGuIX and 68 Ga-DOTAGA-AGuIX, as a dual-modality PET/MRI probe (46) . Actually, due to the small size (2.5 AE 0.1 nm) and the biodegradable properties of AGuIX, the NPs were cleared from the blood quickly into the urine via the kidneys. The small amount of remaining activity wileyonlinelibrary.com/journal/cmmi wileyonlinelibrary.com/journal/cmmi wileyonlinelibrary.com/journal/cmmi in all untargeted tissues, such as liver (0.25 %ID/g), showed that this agent could be a suitable probe (46).
Tumor uptake
One of the most important parameters for evaluating the efficiency of a contrast agent is tumor uptake in comparison with other organs (especially vital organs). First of all, it is better to begin by explaining the uptake mechanism. Most solid tumors have blood vessels with a defective structure; therefore, they exhibit enhanced vascular permeability known as enhanced permeability and retention (EPR). By EPR, drugs could be directed to the tumor environment in a passive way rather than through biochemical receptors (47) . On the other hand, the transport of nanoscale hydrophilic biomolecules is usually done using endocytosis, which is a form of active transport. In this process, a cell absorbs materials by enclosing them in vesicles or vacuoles pinched off from its cytoplasmic membrane. There are various types of endocytosis and different types of NPs reveal a chosen pathway for cellular internalization. Also, whereas one of the main approaches in the development of nanomedicines for imaging and therapy is to confirm that the NPs can easily enter the cells, having knowledge about the effecting parameters on uptake is essential (48) . Studies have shown that the effecting factors on cellular uptake are size and shape, composition, charge, and surface chemistry of the NPs (48) . From the analyzed studies we concluded that the size range of 20-200 nm can be used for molecular imaging, although it is better to try to achieve as small a size as it is possible.
After reviewing the 49 studies, we extracted the amounts of tumor uptake of 19 studies. Among the selected studies, Arginine-glycine-aspartic (RGD) peptide, which has high affinity to bind tumor with integrin a v b 3 expression, was chosen for the synthesis of seven dual contrast agents (49) (50) (51) (52) (53) (54) (55) . It was shown that the tumor uptake with agents conjugated to RGD was considerably higher than with agents not-conjugated to RGD. Therefore, the high tumor uptake could be due to RGD. As shown in Table 4 , the highest uptake was found for 64 Cu-DOTA-IO-RGD (10.1 AE 2.1 %ID/g) at 4 h post injection in tumor α v β 3 integrin expression. In that study, the non-targeted particle (without RGD) 64 Cu-DOTA-IO showed considerably lower tumor uptake compared with the RGD conjugated nanoparticle, but their liver and kidney uptakes had no significant difference at different time points (50) .
The lowest tumor uptake reported was for 111 In-mAbMB-SPION. The quantities of tumor uptake are 2.2 and 3.8%ID/g at 24 and 72 hours post-injection, respectively (56) . This result could be because of the size of the compound (69.6 nm) in comparison with another contrast agent, 64 Cu-NOTA-SPION-cRGD-DOX, which has higher tumor uptake (49) . There is, however, no additional data about other time points. Concerning the effect of particle size, by comparing two contrast agents, 64 Cu-Cy5.5-IONPs and 64 Cu-DOTA-IO-c(RGDyK), it is found that the tumor uptake for the smaller particle size is higher than for the other one (53,57).
Size effect
Size is one of the most important issues in the biodistribution of NPs. An earlier study showed that the uptake efficiency of 100 nm size particles by the intestinal tissue was 15-250 fold higher compared to larger size particles (58) . Another study reported that moving from 200 nm to 70 nm leads to 27 times higher uptakes in target organs (59) . Natarjan et al. investigated the tumor uptake and biodistribution of 111 In-IONPS-ChL6 with three different sizes and showed that the tumor uptakes at 48 h post injection were 9.0 AE 0.8 (for a size of 20 nm), 3.0 AE 0.3 (for 30 nm), and 4.5 AE 0.8 (for 100 nm) (60) . Therefore, concluding that lower size always gives better tumor uptake may not be correct but as shown in Tables 2 and 4 the majority of the dual probes are below 100 (the minimum size being 2.5 and the average size about 43 nm). Among all studies presented in Table 2 , the highest tumor uptake was observed for NPs with a hydrodynamic size of 45, 20 and 19 nm with the tumor uptakes of 10.1 AE 2.1 % (50), 9.0 AE 0.8% (60) and 8.45% (57) respectively. NPs with small size (less than 100 nm) are transported and taken up by the target organs more readily, whereas the larger NPs are likely to remain at the injection site (61).
Coating
Another crucial factor in tumor uptake is the coating. Among all 49 studies presented in Table 2 , more than 36% used dextran, whereas about 26% used PEG, as a coating. Some studies show that a small hydrodynamic size (less than 100 nm) and low zetapotential offer the opportunity to control circulation time and avoid immediate RES clearance, where this is desired for targeting applications (61, 62) . Cui et al. showed that the use of longer-chain PEGylated NPs (10 KDa, n ≈ 227 and À10 mV) resulted in a delayed clearance of NPs as compared to the shorter-chain PEGylated NPs (2KDa with n ≈ 45, and zeta potential of +10 mV). Therefore, the length of the PEG chain and the zeta potential of NPs play important roles in biodistribution (61) . Previous studies confirm the fact that particle size and surface properties also play a significant role in enhancing lymphatic transport (63, 64) . PEGylation can improve the uptake in lymph nodes and increase accumulation at the disease site by reducing the nonspecific interaction between particles and proteins of the biological milieu, thus causing a longer blood circulation time (61, 65) . On the other (77) hand, several studies confirmed that Dextran coated NPs resulted in RES uptakes due to the protein corona formation (see the section 4.6) (66-70).
Transverse relaxivity (r 2 )
In some of these 49 studies, the values of the transverse relaxivity (r 2 ) have been mentioned precisely. There are some studies that investigated the relationship between r 2 and particle characteristics, such as size and coating. They showed that as coating thickness increases, r 2 and r 1 decrease dramatically and found no effect on relaxivity with changing pH (71, 72) . A recent study showed that the impact of charge on magnetic properties is much higher than that of coating thickness. Particles with positive surface charges showed higher r 2 /r 1 ratios (73) . For a type of NPs commonly used as MRI contrast agent, i.e. superparamagnetic iron oxide NPs, r 2 is especially enhanced due to rapid diffusion and exchange of water molecules surrounding the magnetic contrast agents (74). As mentioned, some studies examined the effect of coating type. They showed that iron NPs with silica coating have the highest r 2 (628 mM À1 s À1 in a magnetic field of 1.5 T) in comparison with other coatings (75) and also that r 2 depends on the level of hydrophilicity of the coating material, with the highest r 2 mentioned in a study with hydrophilic Polyethylenimine (PEI) ligand coated nanocrystals (74) . According to r 2 data extracted from the 49 studies, the lowest r 2 (2.54 mM -1 s -1 at 60 MHz) results from using 64 Cu-Apoferretinas a triple-modality contrast agent. This could be because of the relatively high coating thickness (76) . However, the highest value (283.7 mM -1 s -1 ) in the same magnetic field, relates to 124 I-TCL-SPION as an Optical/PET/MRI contrast agent. The main cause could be the size of NPs (77) .
Consequently, based on the specified papers and other investigations on r 2 , an appropriate contrast agent in images using MRI and other dual modality systems that include MRI is an agent with a high r 2 that decreases the signal in T 2 -weighted images. Also, for in vivo biomedical applications such as biomarker targeted delivery and molecular imaging, it is important to use NPs with smaller overall size in order to achieve efficient delivery and rapid clearance of bioconjugated NPs (74) . Therefore, small NPs with hydrophilic coating should be suitable.
The transverse relaxivities of some multimodality contrast agents mentioned in the analyzed studies are shown in Table 5 .
Protein corona
When NPs are exposed to the biological milieu, their surfaces become covered with a variety of proteins and biomolecules, which are called the protein corona (78) (79) (80) . Studies showed that the protein corona reduces the targeting capability of surface modified NPs by covering or affecting the active sites of these nanoprobes (80) (81) (82) . Usually, in vitro results (i.e. serum-free medium or 10% serum) are very promising and confirm the high capability of the new functionalized NPs for targeting the desired cells. However, the in vivo results are often disappointing and show lower targeting yields and undesirable biodistribution (i.e. NPs taken up by the RES instead of the desired tumor tissue) (69, 83, 84) . In a study carried out by Shanehsazzadeh et al. after obtaining very promising in vitro results the in vivo results were disappointing (>80% of ID/g of the nanoprobe was taken up by RES). This was not only due to the targeting site being covered by the protein corona, but also because of absorption of opsonin-based proteins at the surface of nanoprobes (69) . Studies have shown that there are two main reasons for high RES uptakes: first, the opsonin based proteins are absorbed to the surface of NPs, and, second the ability of the protein corona to cover the targeting species. For instance, Dawson et al. showed that the targeting ability of transferrin-conjugated NPs was significantly reduced after interaction of NPs with serum proteins (85) . More specifically, the protein corona shielded transferrin from binding to its targeted receptors. This second mechanism is related to low blood circulation time of the nanoprobes. Protein corona not only alters the biological fate of the NPs but it also changes their magnetic properties (86) (87) (88) . Studies show that the r 2 is very much dependent on the functional group and the surface charge of the SPIONs' coating. Therefore, due to changes in hydrodynamic size and charge of NPs after being exposed to the biological milieu, their magnetic properties changed (73, 88, 89) .
CONCLUSION
In this review we analyzed the main factors that affect the uptakes of the dual modality probes in PET/MRI. Evaluating the liver uptake of selected studies showed that the bigger size of contrast agent NPs causes the more liver uptake. The kind of coating is another important reason for high liver uptake (dextran causes higher liver uptake). Furthermore, some molecules and proteins such as opsonins are taken up by cells of the RES. From the published studies we concluded that a size range of 20-200 nm can be used for molecular imaging; although since tumor uptake is higher with smaller particle size, as small a size as possible should be achieved.
In terms of the biomarkers, the best targeting results among the published studies were related to nanoprobes that used peptides. One of these molecules is RGD, which has been conjugated with some contrast agents and shown to result in a higher tumor uptake than others.
In conclusion, the best targeting results according to the selected studies are generally with peptide or engineered mAb (with lower molecular weights) with an approximate hydrodynamic size of 40 nm, PEGylated radio labeled with 64 Cu or 68 Ga. However, there are some exceptions and some surprising nano probes with a different composition.
